These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 24189173)

  • 21. Sex differences in opioid use and medical issues during buprenorphine/naloxone treatment.
    Barbosa-Leiker C; McPherson S; Layton ME; Burduli E; Roll JM; Ling W
    Am J Drug Alcohol Abuse; 2018; 44(4):488-496. PubMed ID: 29672167
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient perspectives on buprenorphine/naloxone treatment in the context of HIV care.
    Egan JE; Netherland J; Gass J; Finkelstein R; Weiss L;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S46-53. PubMed ID: 21317594
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of buprenorphine treatment for opioid dependence in 3 settings.
    Miotto K; Hillhouse M; Donovick R; Cunningham-Rathner J; Charuvastra C; Torrington M; Esagoff AE; Ling W
    J Addict Med; 2012 Mar; 6(1):68-76. PubMed ID: 22105061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Group medication management for buprenorphine/naloxone in opioid-dependent veterans.
    Berger R; Pulido C; Lacro J; Groban S; Robinson S
    J Addict Med; 2014; 8(6):415-20. PubMed ID: 25275875
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Who benefits from additional drug counseling among prescription opioid-dependent patients receiving buprenorphine-naloxone and standard medical management?
    Weiss RD; Griffin ML; Potter JS; Dodd DR; Dreifuss JA; Connery HS; Carroll KM
    Drug Alcohol Depend; 2014 Jul; 140():118-22. PubMed ID: 24831754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-Effectiveness of Buprenorphine-Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse.
    Murphy SM; McCollister KE; Leff JA; Yang X; Jeng PJ; Lee JD; Nunes EV; Novo P; Rotrosen J; Schackman BR
    Ann Intern Med; 2019 Jan; 170(2):90-98. PubMed ID: 30557443
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Just call it "treatment".
    Friedmann PD; Schwartz RP
    Addict Sci Clin Pract; 2012 Jun; 7(1):10. PubMed ID: 23186149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial.
    Woody GE; Bruce D; Korthuis PT; Chhatre S; Poole S; Hillhouse M; Jacobs P; Sorensen J; Saxon AJ; Metzger D; Ling W
    J Acquir Immune Defic Syndr; 2014 Jul; 66(3):288-93. PubMed ID: 24751432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brief versus extended counseling along with buprenorphine/naloxone for HIV-infected opioid dependent patients.
    Tetrault JM; Moore BA; Barry DT; O'Connor PG; Schottenfeld R; Fiellin DA; Fiellin LE
    J Subst Abuse Treat; 2012 Dec; 43(4):433-9. PubMed ID: 22938914
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics.
    Korthuis PT; Tozzi MJ; Nandi V; Fiellin DA; Weiss L; Egan JE; Botsko M; Acosta A; Gourevitch MN; Hersh D; Hsu J; Boverman J; Altice FL;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S39-45. PubMed ID: 21317593
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of a sequential multiple assignment randomized trial to test contingency management and an integrated behavioral economic and mindfulness intervention for buprenorphine-naloxone medication adherence for opioid use disorder.
    Peter SC; Murphy JG; Witkiewitz K; Hand SB; Thomas F; Johnson KC; Cowan R; Harris M; Derefinko KJ
    Trials; 2023 Mar; 24(1):237. PubMed ID: 36991453
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emergency Department-Initiated Buprenorphine for Opioid Dependence with Continuation in Primary Care: Outcomes During and After Intervention.
    D'Onofrio G; Chawarski MC; O'Connor PG; Pantalon MV; Busch SH; Owens PH; Hawk K; Bernstein SL; Fiellin DA
    J Gen Intern Med; 2017 Jun; 32(6):660-666. PubMed ID: 28194688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Opioid addicted buprenorphine injectors: drug use during and after 12-weeks of buprenorphine-naloxone or methadone in the Republic of Georgia.
    Piralishvili G; Otiashvili D; Sikharulidze Z; Kamkamidze G; Poole S; Woody GE
    J Subst Abuse Treat; 2015 Mar; 50():32-7. PubMed ID: 25456093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Readiness and recovery: Transferring between methadone and buprenorphine/naloxone for the treatment of opioid use disorder.
    Bishop B; Gilmour J; Deering D
    Int J Ment Health Nurs; 2019 Feb; 28(1):226-236. PubMed ID: 30019812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative.
    Weiss L; Netherland J; Egan JE; Flanigan TP; Fiellin DA; Finkelstein R; Altice FL;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S68-75. PubMed ID: 21317597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risky Sexual Behavior Among Individuals Receiving Buprenorphine/Naloxone Opiate Dependency Treatment: HIV Prevention Trials Network (HPTN) 058.
    Shava E; Lipira LE; Beauchamp GG; Donnell DJ; Lockman S; Ruan Y; Shao Y
    J Acquir Immune Defic Syndr; 2018 Jul; 78(3):300-307. PubMed ID: 29557855
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The BHIVES collaborative: organization and evaluation of a multisite demonstration of integrated buprenorphine/naloxone and HIV treatment.
    Weiss L; Egan JE; Botsko M; Netherland J; Fiellin DA; Finkelstein R
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S7-13. PubMed ID: 21317598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction.
    Worley MJ; Heinzerling KG; Shoptaw S; Ling W
    Addiction; 2017 Jul; 112(7):1202-1209. PubMed ID: 28164407
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use and misuse of opioid replacement therapies: a Queensland study.
    Smirnov A; Kemp R
    Subst Use Misuse; 2012 Jan; 47(1):78-85. PubMed ID: 22216993
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A mixed methods study of HIV-related services in buprenorphine treatment.
    Knudsen HK; Cook J; Lofwall MR; Walsh SL; Studts JL; Havens JR
    Subst Abuse Treat Prev Policy; 2017 Aug; 12(1):37. PubMed ID: 28814313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.